This is a working overview of GIP受体, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
There are additives, such as STP Oil Treatment, and some racing oils such as PurOl, PennGrade 1, and Valvoline VR-1, Kixx Hydraulic Oil which are available in the retail market with the necessary amount of ZDDP for engines using increased valve spring pressures.
=== Benign prostatic hyperplasia and prostate cancer === Dutasteride is used for treating BPH, colloquially known as an "enlarged prostate". It is approved by the Food and Drug Administration (FDA) in the U.S. for this indication. A 2010 Cochrane review found a 25–26% reduction in the risk of developing prostate cancer with 5α-reductase inhibitor chemoprevention.
=== Silicon batteries === The company started promoting its silicon-graphite-electrode batteries in 2019 and ceased development of its germanium-based batteries in 2020. The company sent germanium sample batteries to manufacturers in place of silicon sample batteries. The company's CEO said the germanium batteries were only developed as proof-of-concept, were only meant to be sold in small quantities, and that they were never released because they weren't sufficiently differentiated from the rest of the market. Group14 Technologies has developed silicon nanoparticles called SCC55 which allow lithium-silicon batteries to charge from 10% to 80% state-of-charge in 10 minutes. StoreDot tested the material for use in their silicon batteries. The company was looking in 2023 for suppliers capable of manufacturing thousands of tonnes of this material, which is critical for their business. The battery cells have a sponge-like carbon electrode imbued with silicon nanoparticles that react with the lithium ions, keeping the silicon's expansion within the carbon "sponge".
Sources: en.wikipedia.org
== Research == Bifidobacterium animalis subspecies lactis BB-12 administered in combination with other probiotics has shown "a trend toward increased remission" in a study of 32 patients with ulcerative colitis. Research on Bifidobacterium animalis supplementation in preterm infants, as detailed in the systematic review by Szajewska et al., a meta-analysis of four randomized controlled trials (RCTs) involving a total of 324 infants, has shown promising results. These include increased fecal bifidobacteria counts, reduced Enterobacteriaceae and Clostridium spp counts, as well as improvements in stool pH, fecal calprotectin concentrations, fecal immunoglobulin A levels, and short-chain fatty acid concentrations. However, the analysis did not find significant effects on the risk of necrotizing enterocolitis stage ≥2, risk of sepsis, or use of antibiotics compared to controls.
SJIA is diagnosed clinically and corroborated by typical test findings; it is a diagnosis of exclusion. A child suspected of having sJIA should undergo a full evaluation for infection and cancer, including blood and urine cultures, imaging tests, and bone marrow exams to rule out leukemia or lymphoma. The International League of Associations for Rheumatology criteria for sJIA include arthritis, ≥2 weeks of daily fever, and symptoms like organomegaly, lymphadenopathy, serositis, or non-fixed/evanescent rash. Laboratory abnormalities are typical, but no specific tests are available for sJIA. Treatment for a disease varies greatly, requiring consideration of involvement, systemic characteristics, and MAS presence. Nonsteroidal anti-inflammatory medications can be safely administered for analgesic and antipyretic effects without altering initial diagnostic assessment results. Clinical trials show that anti-interleukin-6 and anti-interleukin-1 drugs are effective in managing systemic symptoms. Studies show that 40% of children with SJIA have a monocyclic disease history, recovering after varying periods. A small percentage experience a polycyclic course, with over half having a prolonged disease course. Juvenile idiopathic arthritis (JIA) is the most prevalent rheumatic illness in children, affecting 1 to 4 out of every 1000. SJIA accounts for 10% to 20% of cases, with peak presentation between 1 and 5 years. Children of all genders and ethnic origins are equally affected.
Half-Life 2: Episode Three is a canceled first-person shooter game developed by Valve. It was planned as the last in a trilogy of episodic games continuing the story of Half-Life 2 (2004). Valve announced Episode Three in May 2006, with a release planned for 2007. Following the cliffhanger ending of Episode Two (2007), it was widely anticipated. Episode Three was to be set in the Arctic and introduce elements such as an ice gun and a blob-like enemy. Marc Laidlaw, the writer for the Half-Life series, intended it to end the Half-Life 2 story arc. Little information was released over the following years, and in 2011 Wired described it as vaporware. Valve eventually canceled Episode Three as they had become fatigued with Half-Life and could not settle on a direction. Additionally, they wanted to create more ambitious games and felt limited by the episodic format. They delayed development of a new Half-Life game until their new game engine, Source 2, was complete. Laidlaw left Valve in 2016. In 2017, he released a short story that journalists speculated was a summary of the Episode Three plot. In response, fans launched projects attempting to recreate Episode Three. After canceling several further Half-Life games, Valve released a virtual reality game, Half-Life: Alyx, in 2020.
Sources: en.wikipedia.org
== Awards and honors == Okan won the Publication Incentive Award for his work. In addition to his election to the fellowship of the Royal Colleges of Physicians of Edinburgh, Ireland and London; his memberships include the Turkish Society of Dermatology, American Society of Dermatology, Health Volunteers Overseas, and European Academy of Dermatology and Venereology.
== Geonium atom == A geonium atom is a pseudo-atomic system that consists of a single electron or ion stored in a Penning trap which is 'bound' to the remaining Earth, hence the term 'geonium'. The name was coined by H.G. Dehmelt. In the typical case, the trapped system consists of only one particle or ion. Such a quantum system is determined by quantum states of one particle, like in the hydrogen atom. Hydrogen consists of two particles, the nucleus and electron, but the electron motion relative to the nucleus is equivalent to one particle in an external field, see center-of-mass frame. The properties of geonium are different from a typical atom. The charge undergoes cyclotron motion around the trap axis and oscillates along the axis. An inhomogeneous magnetic "bottle field" is applied to measure the quantum properties by the "continuous Stern-Gerlach" technique. Energy levels and g-factor of the particle can be measured with high precision. Van Dyck, et al. explored the magnetic splitting of geonium spectra in 1978 and in 1987 published high-precision measurements of electron and positron g-factors, which constrained the electron radius.
The three substrates of this enzyme are (S)-1-pyrroline-5-carboxylic acid, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are L-proline and oxidised (NAD+). Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-proline:NAD(P)+ 5-oxidoreductase. Other names in common use include proline oxidase, L-proline oxidase, 1-pyrroline-5-carboxylate reductase, NADPH-L-Delta1-pyrroline carboxylic acid reductase, and L-proline-NAD(P)+ 5-oxidoreductase. This enzyme participates in arginine and proline metabolism.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。